about
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapyCarcinogenetic mechanisms of endocrine disruptors in female cancers (Review)Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.What sampling device is the most appropriate for vaginal vault cytology in gynaecological cancer follow up?Antiblastic treatment, for solid tumors, during pregnancy: a crucial decision.Obstetrical, fetal and postnatal effects of gestational antiblastic chemotherapy: how to counsel cancer patients.Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?Is effective and safe a radiochemotherapy approach in elderly cancer patients? A review.Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk.Endocrine disruptors and female cancer: Informing the patients (Review).Special issues in fertility preservation for gynecologic malignancies.Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients.Ospemifene: a safe treatment of vaginal atrophy.Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?Gonadal agenesis with hypoplastic paramesonephric ducts (PMNDs) derivatives in dizygotic twins.Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences.Breast cancer risk of hormonal contraception: Counselling considering new evidenceApproach to sexual dysfunction in women with cancerOvarian transposition in young women and fertility sparingLetter to the Editor - DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer
P50
Q26774358-24AE486C-77D0-4F91-A292-964C5F2B2A61Q28596765-894EC706-D999-4F54-8492-B6B21C69F99BQ33648514-C5E8631A-A10D-4263-BCD8-5BF1B0DD4B92Q34675374-2CEB0670-4939-431F-9465-BD1779D7B759Q36322382-432C8971-996F-491D-A12E-7EC87831C096Q38054919-98162F5E-0103-4BCF-ADDF-8D5EEDE84363Q38054922-B328A8AF-17E6-40C9-A7B2-FFA0D59E0EEAQ38147864-A25F8004-F2EA-42B5-A202-BED9C1BE135DQ38150377-D66D8E0B-A3DE-438D-BECC-FC487248712CQ38171959-FE6002E2-E005-477A-AC4F-43232D6D3056Q38495995-BE46697C-3280-468A-AC6C-8E5C8D6AC70AQ38584439-FBE94549-467B-4A44-9C71-DE25658837A3Q38828142-122D5270-23E8-43FC-8C7E-FF5FBE0099DCQ38979470-AD4FA26A-CA5B-4D7E-AA96-84349D34CB4EQ47127757-099E738D-675B-4287-8695-C32FFFC87D24Q47348217-01DF9298-4FFE-48E0-8AD2-AAAB4EE01AF2Q49824053-9017EE4E-F76D-4BE8-BAE0-A1FDA38BE18FQ53010579-72EA205C-80C7-455E-BEAC-652799E98CBBQ55142706-FB6B9711-D7A0-4C06-B2E0-E72A3FA1D6A5Q90245513-41E0843A-499C-4FFB-8104-2A730023BB73Q91594698-D199E229-5F9A-40E1-A6C1-FC4F369BE734Q95551853-405560C3-F41F-4640-9283-D079685527FBQ95554227-42A59C91-1C35-45D8-8E87-28E6B617AE83
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Lino Del Pup
@en
Lino Del Pup
@nl
type
label
Lino Del Pup
@en
Lino Del Pup
@nl
prefLabel
Lino Del Pup
@en
Lino Del Pup
@nl
P31
P496
0000-0003-2979-3844